BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) – Jefferies Group boosted their FY2016 earnings per share estimates for BioCryst Pharmaceuticals in a research note issued on Monday. Jefferies Group analyst B. Abrahams now expects that the firm will post earnings of ($0.90) per share for the year, up from their prior forecast of ($0.99). Jefferies Group currently has a “Hold” rating and a $3.00 price target on the stock. Jefferies Group also issued estimates for BioCryst Pharmaceuticals’ Q4 2016 earnings at ($0.21) EPS, FY2017 earnings at ($0.69) EPS, FY2018 earnings at ($0.58) EPS, FY2019 earnings at ($0.66) EPS and FY2020 earnings at ($0.54) EPS.

A number of other equities analysts have also recently issued reports on BCRX. Zacks Investment Research upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.25 price target on the stock in a research note on Wednesday. HC Wainwright reiterated a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday. FBR & Co reiterated a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday. JPMorgan Chase & Co. reiterated a “hold” rating on shares of BioCryst Pharmaceuticals in a research note on Friday, August 5th. Finally, JMP Securities cut shares of BioCryst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, August 4th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company’s stock. BioCryst Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $7.93.

Earnings History and Estimates for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX) opened at 5.07 on Wednesday. The stock’s market cap is $373.66 million. BioCryst Pharmaceuticals has a 1-year low of $1.63 and a 1-year high of $10.98. The stock has a 50 day moving average of $4.41 and a 200 day moving average of $3.78.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 7th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.08. The firm earned $7.80 million during the quarter, compared to the consensus estimate of $5.94 million. BioCryst Pharmaceuticals had a negative net margin of 313.02% and a negative return on equity of 296.19%. The company’s revenue was down 29.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) earnings per share.

In other news, VP Yarlagadda S. Babu sold 30,000 shares of the company’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $4.06, for a total transaction of $121,800.00. Following the completion of the sale, the vice president now owns 111,428 shares of the company’s stock, valued at approximately $452,397.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of the company’s stock in a transaction dated Tuesday, August 16th. The shares were sold at an average price of $5.00, for a total transaction of $20,232,950.00. The disclosure for this sale can be found here. Insiders own 5.80% of the company’s stock.

Several large investors have recently added to or reduced their stakes in BCRX. BlackRock Group LTD raised its stake in BioCryst Pharmaceuticals by 4.4% in the third quarter. BlackRock Group LTD now owns 23,530 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 984 shares during the last quarter. Creative Planning raised its stake in BioCryst Pharmaceuticals by 48.8% in the third quarter. Creative Planning now owns 24,400 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 8,000 shares during the last quarter. Morgan Stanley raised its stake in BioCryst Pharmaceuticals by 50.8% in the third quarter. Morgan Stanley now owns 25,323 shares of the biotechnology company’s stock valued at $112,000 after buying an additional 8,529 shares during the last quarter. Commonwealth Equity Services Inc raised its stake in BioCryst Pharmaceuticals by 15.7% in the second quarter. Commonwealth Equity Services Inc now owns 40,255 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 5,450 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in BioCryst Pharmaceuticals by 29.8% in the third quarter. Wells Fargo & Company MN now owns 28,330 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 6,500 shares in the last quarter. 70.29% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

5 Day Chart for NASDAQ:BCRX

Receive News & Stock Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.